Brazil Phase 2 Pivotal clinical trial of COVI-MSC is now authorized to proceed. The study will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients ...
The "Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2025" report has been added to ResearchAndMarkets.com's offering. MSCs are multipotent cells that have been ...
SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia (BCDA) ®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback